← 返回

利用嵌合 miRNA 簇平台对细胞治疗多靶点基因的高效 shRNA 敲低

英文原题:Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform.

查看英文原题

Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform.

PubMed 2023/09/20(内容时间) Mol Ther Nucleic Acids Q1 · IF 6.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

基因组工程是优化或精细调节细胞功能的强大工具,可用于细胞免疫治疗。但同时编辑多个基因会带来重要的生物学和技术挑战。基于短发夹RNA(shRNA)的细胞工程可绕过这些限制,是基于CRISPR基因编辑的有效替代方案。本文介绍一种基于微小RNA(miRNA)的多重shRNA平台:将高效miRNA骨架组合成嵌合簇,可递送最多4条shRNA样序列。由于表达盒体积有限,可在一步流程中与所有CAR组分一并导入,从而简化工程化CAR-T 细胞制备。该shRNA平台采用即插即用设计,可替换各条shRNA来源的引导序列而不影响系统性能。通过合理选择靶序列,无需基因编辑即可实现功能性基因敲除或精细调节靶基因表达。该策略可简便、安全、高效且可调地同时调控多个靶基因,有助于在工程化细胞转录组中引入多个具有功能意义的改动,从而提高其在实体瘤等复杂环境中的表现。

展开英文摘要原文

Genome engineering technologies are powerful tools in cell-based immunotherapy to optimize or fine-tune cell functionalities.

However, their use for multiple gene edits poses relevant biological and technical challenges. Short hairpin RNA (shRNA)-based cell engineering bypasses these criticalities and represents a valid alternative to CRISPR-based gene editing.

Here, we describe a microRNA (miRNA)-based multiplex shRNA platform obtained by combining highly efficient miRNA scaffolds into a chimeric cluster, to deliver up to four shRNA-like sequences. Thanks to its limited size, our cassette could be deployed in a one-step process along with all the CAR components, streamlining the generation of engineered CAR T cells. The plug-and-play design of the shRNA platform allowed us to swap each shRNA-derived guide sequence without affecting the system performance.

Appropriately choosing the target sequences, we were able to either achieve a functional KO, or fine-tune the expression levels of the target genes, all without the need for gene editing. Through our strategy we achieved easy, safe, efficient, and tunable modulation of multiple target genes simultaneously. This approach allows for the effective introduction of multiple functionally relevant tweaks in the transcriptome of the engineered cells, which may lead to increased performance in challenging environments, e. g. , solid tumors.

论文信息

作者
Rossi M、Steklov M、Huberty F、Nguyen T、Marijsse J、Jacques-Hespel C、Najm P、Lonez C
单位
Celyad Oncology, 1435 Mont-Saint-Guibert, Belgium.Belgium
期刊
Molecular therapy. Nucleic acids2023 Dec 12
原文标识
PubMed 37799328 · DOI 10.1016/j.omtn.2023.102038